Aragon Pharmaceuticals, Inc. (Acquired by Johnson & Johnson)
12780 El Camino Real
Suite 301
San Diego
California
92130
United States
Tel: 858-369-7600
Fax: 858-369-7650
Website: http://www.aragonpharmaceuticals.com/
Email: info@aragonpharm.com
17 articles with Aragon Pharmaceuticals, Inc. (Acquired by Johnson & Johnson)
-
venBio Global Strategic Fund IV will invest primarily in drug companies focused on developing therapies for unmet medical needs.
-
Alder CEO Is Stepping Down
3/21/2018
Alder BioPharmaceuticals announced that Randall Schatzman, the company’s president, chief executive officer and director, will be stepping down. -
Johnson & Johnson Completes Acquisition of Aragon Pharmaceuticals, Inc.
8/20/2013
-
Johnson & Johnson to Buy Aragon Pharmaceuticals, Inc. for Up to $1 Billion
6/17/2013
-
Aragon Pharmaceuticals, Inc. Announces First Patient Dosed in Phase I Study of ARN-810 in Estrogen Receptor Positive Breast Cancer
4/4/2013
-
Aragon Pharmaceuticals, Inc. Announces Key Strategic Hire
2/11/2013
-
Aragon Pharmaceuticals, Inc. Wins Key Legal Ruling Against Medivation, Inc.
1/4/2013
-
Aragon Pharmaceuticals, Inc. Snags $50 Million Series D
10/4/2012
-
Aragon Pharmaceuticals, Inc. Raises $50 Million
10/1/2012
-
Aragon Pharmaceuticals, Inc. Announces Clinical Results from Ongoing Phase II Trial Confirming Robust Anti-Tumor Activity and Tolerability of ARN-509 in Three Different Patient Populations of Castration Resistant Prostate Cancer
10/1/2012
-
Aragon Pharmaceuticals, Inc. Announces Appointment of Faheem Hasnain as Independent Director
8/28/2012
-
Aragon Pharmaceuticals, Inc. Nabs $42 Million, Targets Hormone-Driven Cancers
3/6/2012
-
Aragon Pharmaceuticals, Inc. to Present at the 10th Annual Biotechnology Industry Organization (BIO) Investor Forum on October 26
10/20/2011
-
Aragon Pharmaceuticals, Inc. Doses First Patient in Phase 1/2 Clinical Trial of ARN-509 for Castration-Resistant Prostate Cancer
8/9/2010
-
Aragon Pharmaceuticals, Inc. Appoints Richard A. Heyman CEO
8/2/2010
-
Aragon Pharmaceuticals, Inc. Secures $22 Million in Series B Financing
4/22/2010
-
Aragon Pharmaceuticals Announces $8 Million Series A Financing
5/20/2009